PDF Print E-mail

Cotara® Oncology

Tumor Necrosis Therapy

Peregrine's targeted Tumor Necrosis Therapy technology (TNT) uses monoclonal antibodies designed to bind to DNA-histone H1 complex which is exposed primarily in the dead and dying cells that are present in abundance at the center of tumors. TNT antibodies are capable of carrying a variety of therapeutic agents, including radioisotopes, into the interior of solid tumors where they kill the tumor from the inside out. Peregrine's lead TNT-based brain cancer therapy is Cotara, an antibody conjugated to a therapeutic radioisotope that binds to the core of the tumor mass and kills adjacent cells.


Currently positioned for Phase III clinical development, Cotara is a novel experimental therapy for the treatment of glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara links a radioactive isotope, iodine 131, to a targeting monoclonal antibody. Its targeting mechanism enables it to home in on the dead and dying cells at the center of solid tumors, including brain tumors, delivering its radioactive “payload” directly to the center of the tumor mass and thereby destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue.

Localized to the necrotic core of a brain tumor,
Cotara irradiates from the inside-out.

Cotara is delivered directly into the center of the brain tumor through a special method developed by the NIH called convection-enhanced delivery (CED). This method can deliver up to a 10,000-fold greater concentration in exposure to the therapy than conventional IV drug administration.

Cotara has been granted orphan drug status and Fast Track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. FDA.

Click here to learn more about our Cotara clinical program.